Edition:
United States

Roche Holding AG (RO.S)

RO.S on Swiss Exchange

227.60CHF
21 Feb 2018
Change (% chg)

CHF0.80 (+0.35%)
Prev Close
CHF226.80
Open
CHF226.80
Day's High
CHF227.60
Day's Low
CHF224.80
Volume
26,361
Avg. Vol
34,565
52-wk High
CHF271.75
52-wk Low
CHF219.80

Chart for

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.94
Market Cap(Mil.): CHF194,794.09
Shares Outstanding(Mil.): 862.56
Dividend: 8.30
Yield (%): 3.71

Financials

  Industry Sector
P/E (TTM): -- 32.23 16.73
EPS (TTM): -- -- --
ROI: -- 14.02 35.60
ROE: -- 15.49 17.23

PRESS DIGEST- Wall Street Journal - Feb 16

Feb 16 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

Feb 16 2018

Roche to buy Flatiron Health for $1.9 billion to expand cancer care portfolio

Swiss drugmaker Roche Holding AG said on Thursday it would buy the rest of U.S. cancer data company Flatiron Health for $1.9 billion to speed development of cancer medicines and support its efforts to price them based on how well they work.

Feb 15 2018

UPDATE 2-Roche to buy Flatiron Health for $1.9 bln to expand cancer care portfolio

Feb 15 Swiss drugmaker Roche Holding AG said on Thursday it would buy the rest of U.S. cancer data company Flatiron Health for $1.9 billion to speed development of cancer medicines and support its efforts to price them based on how well they work.

Feb 15 2018

Roche to buy Flatiron Health for $1.9 bln

Feb 15 Drugmaker Roche Holding AG said on Thursday it would buy the rest of the privately held oncology data company Flatiron Health Inc for $1.9 billion to speed up development and delivery of breakthrough medicines for cancer patients.

Feb 15 2018

BRIEF-Roche To Acquire Flatiron Health

* ROCHE SAYS UNDER TERMS OF THE AGREEMENT, ROCHE WILL MAKE A PAYMENT OF $1.9 BILLION TO FLATIRON HEALTH ON A FULLY DILUTED BASIS

Feb 15 2018

BRIEF-Health Canada Approves Roche's Ocrevus For Type of Multiple Sclerosis

* HEALTH CANADA APPROVES OCREVUS® (OCRELIZUMAB) FOR CANADIANS LIVING WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS)

Feb 15 2018

BRIEF-Shire says too early to see impact Of Roche competitor Hemlibra

* CFO SAYS SEES IT IS STILL EARLY TO ASSESS IMPACT OF COMPETITOR ROCHE'S HEMLIBRA ON HEMOPHILIA FRANCHISE Further company coverage: (Reporting By London Bureau)

Feb 14 2018

BRIEF-Roche Receives FDA Clearance For Factor Ii And Factor V Test On The Cobas® 4800 System

* ROCHE RECEIVES FDA CLEARANCE FOR FACTOR II AND FACTOR V TEST ON THE COBAS® 4800 SYSTEM Source text for Eikon: Further company coverage:

Feb 13 2018

Drug copies ready to take next bite out of Roche's cancer sales

LONDON European oncologists will soon get their hands on cut-price copies of breast cancer drug Herceptin, turning the screws on maker Roche and giving another boost to a new breed of companies focused on so-called biosimilars.

Feb 13 2018

Drug copies ready to take next bite out of Roche's cancer sales

LONDON, Feb 13 European oncologists will soon get their hands on cut-price copies of breast cancer drug Herceptin, turning the screws on maker Roche and giving another boost to a new breed of companies focused on so-called biosimilars.

Feb 13 2018

Earnings vs. Estimates